Prognostic value of troponin i levels for predicting adverse cardiovascular outcomes in postmenopausal women undergoing cardiac surgery

Joshua D. Stearns, Victor G. Dávila-Román, Benico Barzilai, Richard Thompson, Kelly L. Grogan, Betsy Thomas, Charles W. Hogue

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Adverse cardiac events that follow cardiac surgery are an important source of perioperative morbidity and mortality for women. Troponin I provides a sensitive measure of cardiac injury, but the levels after cardiac surgery may vary between sexes. Our purpose in this study was to evaluate the prognostic value of troponin I levels for predicting cardiovascular complications in postmenopausal women undergoing cardiac surgery. METHODS: The cohort of this study were women enrolled in a previously reported clinical trial evaluating the neuroprotective potential of 17ß-estradiol in elderly women. In that study, 175 postmenopausal women not receiving estrogen replacement therapy and scheduled to undergo coronary artery bypass graft (with or without valve surgery) were prospectively randomized to receive 17ß-estradiol or placebo in a double-blind manner beginning the day before surgery and continuing for 5 days postoperatively. Serial 12-lead electrocardiograms were performed and serum troponin I concentrations were measured before surgery, after surgery on arrival in the intensive care unit, and for the first four postoperative days. The primary end-point of the present study was major adverse cardiovascular events (MACE) defined as a Q-wave myocardial infarction, low cardiac output state or death within 30 days of surgery. The diagnosis of Q-wave myocardial infarction was made independently by two physicians blinded to treatment and patient outcomes with the final diagnosis requiring consensus. Low cardiac output state was defined as cardiac index -1 m -2 for >8 h regardless of treatment. RESULTS: Troponin I levels on postoperative day 1 were predictive of MACE (area under the receiver operator curve = 0.862). A cutoff point for troponin I of >7.6 ng/mL (95% confidence interval, 6.4 -10.8) provided the optimal sensitivity and specificity for identifying patients at risk for MACE. The negative predictive value of a troponin I level for identifying a patient with a composite cardiovascular outcome was high (96%) and the positive predictive value moderate (40%). Postoperative troponin I levels were not different between women receiving perioperative 17β-estradiol treatment compared with placebo and the frequency of MACE was not influenced by 17β-estradiol treatment. CONCLUSIONS: In postmenopausal women, elevated troponin I levels on postoperative day 1 are predictive of MACE. Monitoring of perioperative troponin I levels might provide a means for stratifying patients at risk for adverse cardiovascular events.

Original languageEnglish (US)
Pages (from-to)719-726
Number of pages8
JournalAnesthesia and Analgesia
Volume108
Issue number3
DOIs
StatePublished - Mar 2009

Fingerprint

Troponin
Troponin I
Thoracic Surgery
Estradiol
Low Cardiac Output
Ambulatory Surgical Procedures
Myocardial Infarction
Placebos
Estrogen Replacement Therapy
Coronary Artery Bypass
Intensive Care Units
Electrocardiography
Cohort Studies
Therapeutics
Clinical Trials
Confidence Intervals
Morbidity
Physicians
Transplants
Sensitivity and Specificity

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Prognostic value of troponin i levels for predicting adverse cardiovascular outcomes in postmenopausal women undergoing cardiac surgery. / Stearns, Joshua D.; Dávila-Román, Victor G.; Barzilai, Benico; Thompson, Richard; Grogan, Kelly L.; Thomas, Betsy; Hogue, Charles W.

In: Anesthesia and Analgesia, Vol. 108, No. 3, 03.2009, p. 719-726.

Research output: Contribution to journalArticle

Stearns, Joshua D. ; Dávila-Román, Victor G. ; Barzilai, Benico ; Thompson, Richard ; Grogan, Kelly L. ; Thomas, Betsy ; Hogue, Charles W. / Prognostic value of troponin i levels for predicting adverse cardiovascular outcomes in postmenopausal women undergoing cardiac surgery. In: Anesthesia and Analgesia. 2009 ; Vol. 108, No. 3. pp. 719-726.
@article{966eab3eab64455990903111005d3528,
title = "Prognostic value of troponin i levels for predicting adverse cardiovascular outcomes in postmenopausal women undergoing cardiac surgery",
abstract = "BACKGROUND: Adverse cardiac events that follow cardiac surgery are an important source of perioperative morbidity and mortality for women. Troponin I provides a sensitive measure of cardiac injury, but the levels after cardiac surgery may vary between sexes. Our purpose in this study was to evaluate the prognostic value of troponin I levels for predicting cardiovascular complications in postmenopausal women undergoing cardiac surgery. METHODS: The cohort of this study were women enrolled in a previously reported clinical trial evaluating the neuroprotective potential of 17{\ss}-estradiol in elderly women. In that study, 175 postmenopausal women not receiving estrogen replacement therapy and scheduled to undergo coronary artery bypass graft (with or without valve surgery) were prospectively randomized to receive 17{\ss}-estradiol or placebo in a double-blind manner beginning the day before surgery and continuing for 5 days postoperatively. Serial 12-lead electrocardiograms were performed and serum troponin I concentrations were measured before surgery, after surgery on arrival in the intensive care unit, and for the first four postoperative days. The primary end-point of the present study was major adverse cardiovascular events (MACE) defined as a Q-wave myocardial infarction, low cardiac output state or death within 30 days of surgery. The diagnosis of Q-wave myocardial infarction was made independently by two physicians blinded to treatment and patient outcomes with the final diagnosis requiring consensus. Low cardiac output state was defined as cardiac index -1 m -2 for >8 h regardless of treatment. RESULTS: Troponin I levels on postoperative day 1 were predictive of MACE (area under the receiver operator curve = 0.862). A cutoff point for troponin I of >7.6 ng/mL (95{\%} confidence interval, 6.4 -10.8) provided the optimal sensitivity and specificity for identifying patients at risk for MACE. The negative predictive value of a troponin I level for identifying a patient with a composite cardiovascular outcome was high (96{\%}) and the positive predictive value moderate (40{\%}). Postoperative troponin I levels were not different between women receiving perioperative 17β-estradiol treatment compared with placebo and the frequency of MACE was not influenced by 17β-estradiol treatment. CONCLUSIONS: In postmenopausal women, elevated troponin I levels on postoperative day 1 are predictive of MACE. Monitoring of perioperative troponin I levels might provide a means for stratifying patients at risk for adverse cardiovascular events.",
author = "Stearns, {Joshua D.} and D{\'a}vila-Rom{\'a}n, {Victor G.} and Benico Barzilai and Richard Thompson and Grogan, {Kelly L.} and Betsy Thomas and Hogue, {Charles W.}",
year = "2009",
month = "3",
doi = "10.1213/ane.0b013e318193fe73",
language = "English (US)",
volume = "108",
pages = "719--726",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Prognostic value of troponin i levels for predicting adverse cardiovascular outcomes in postmenopausal women undergoing cardiac surgery

AU - Stearns, Joshua D.

AU - Dávila-Román, Victor G.

AU - Barzilai, Benico

AU - Thompson, Richard

AU - Grogan, Kelly L.

AU - Thomas, Betsy

AU - Hogue, Charles W.

PY - 2009/3

Y1 - 2009/3

N2 - BACKGROUND: Adverse cardiac events that follow cardiac surgery are an important source of perioperative morbidity and mortality for women. Troponin I provides a sensitive measure of cardiac injury, but the levels after cardiac surgery may vary between sexes. Our purpose in this study was to evaluate the prognostic value of troponin I levels for predicting cardiovascular complications in postmenopausal women undergoing cardiac surgery. METHODS: The cohort of this study were women enrolled in a previously reported clinical trial evaluating the neuroprotective potential of 17ß-estradiol in elderly women. In that study, 175 postmenopausal women not receiving estrogen replacement therapy and scheduled to undergo coronary artery bypass graft (with or without valve surgery) were prospectively randomized to receive 17ß-estradiol or placebo in a double-blind manner beginning the day before surgery and continuing for 5 days postoperatively. Serial 12-lead electrocardiograms were performed and serum troponin I concentrations were measured before surgery, after surgery on arrival in the intensive care unit, and for the first four postoperative days. The primary end-point of the present study was major adverse cardiovascular events (MACE) defined as a Q-wave myocardial infarction, low cardiac output state or death within 30 days of surgery. The diagnosis of Q-wave myocardial infarction was made independently by two physicians blinded to treatment and patient outcomes with the final diagnosis requiring consensus. Low cardiac output state was defined as cardiac index -1 m -2 for >8 h regardless of treatment. RESULTS: Troponin I levels on postoperative day 1 were predictive of MACE (area under the receiver operator curve = 0.862). A cutoff point for troponin I of >7.6 ng/mL (95% confidence interval, 6.4 -10.8) provided the optimal sensitivity and specificity for identifying patients at risk for MACE. The negative predictive value of a troponin I level for identifying a patient with a composite cardiovascular outcome was high (96%) and the positive predictive value moderate (40%). Postoperative troponin I levels were not different between women receiving perioperative 17β-estradiol treatment compared with placebo and the frequency of MACE was not influenced by 17β-estradiol treatment. CONCLUSIONS: In postmenopausal women, elevated troponin I levels on postoperative day 1 are predictive of MACE. Monitoring of perioperative troponin I levels might provide a means for stratifying patients at risk for adverse cardiovascular events.

AB - BACKGROUND: Adverse cardiac events that follow cardiac surgery are an important source of perioperative morbidity and mortality for women. Troponin I provides a sensitive measure of cardiac injury, but the levels after cardiac surgery may vary between sexes. Our purpose in this study was to evaluate the prognostic value of troponin I levels for predicting cardiovascular complications in postmenopausal women undergoing cardiac surgery. METHODS: The cohort of this study were women enrolled in a previously reported clinical trial evaluating the neuroprotective potential of 17ß-estradiol in elderly women. In that study, 175 postmenopausal women not receiving estrogen replacement therapy and scheduled to undergo coronary artery bypass graft (with or without valve surgery) were prospectively randomized to receive 17ß-estradiol or placebo in a double-blind manner beginning the day before surgery and continuing for 5 days postoperatively. Serial 12-lead electrocardiograms were performed and serum troponin I concentrations were measured before surgery, after surgery on arrival in the intensive care unit, and for the first four postoperative days. The primary end-point of the present study was major adverse cardiovascular events (MACE) defined as a Q-wave myocardial infarction, low cardiac output state or death within 30 days of surgery. The diagnosis of Q-wave myocardial infarction was made independently by two physicians blinded to treatment and patient outcomes with the final diagnosis requiring consensus. Low cardiac output state was defined as cardiac index -1 m -2 for >8 h regardless of treatment. RESULTS: Troponin I levels on postoperative day 1 were predictive of MACE (area under the receiver operator curve = 0.862). A cutoff point for troponin I of >7.6 ng/mL (95% confidence interval, 6.4 -10.8) provided the optimal sensitivity and specificity for identifying patients at risk for MACE. The negative predictive value of a troponin I level for identifying a patient with a composite cardiovascular outcome was high (96%) and the positive predictive value moderate (40%). Postoperative troponin I levels were not different between women receiving perioperative 17β-estradiol treatment compared with placebo and the frequency of MACE was not influenced by 17β-estradiol treatment. CONCLUSIONS: In postmenopausal women, elevated troponin I levels on postoperative day 1 are predictive of MACE. Monitoring of perioperative troponin I levels might provide a means for stratifying patients at risk for adverse cardiovascular events.

UR - http://www.scopus.com/inward/record.url?scp=61949128321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61949128321&partnerID=8YFLogxK

U2 - 10.1213/ane.0b013e318193fe73

DO - 10.1213/ane.0b013e318193fe73

M3 - Article

C2 - 19224775

AN - SCOPUS:61949128321

VL - 108

SP - 719

EP - 726

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 3

ER -